Authors
Khamitov R.G.1, Ayupova R.F.1, Zhiburt E.B.2
1 Republican blood transfusion station, Ufa
2 Pirogov National Medical and Surgical Center, Moscow
Abstract
Donations and transfusions of anticonvid plasma were studied in the Republic of Bashkortostan. From covalescent donors 81 plasmapheresis was performed from the products of which 240 therapeutic units of anticovid plasma were prepared. It has been established that the recruitment of donors who have undergone COVID-19 infection at the Bashkortostan RSPK allows us to satisfy the need of the region’s medical organizations for anticovid pathogen-reduced plasma. Among the issued plasma, the prevalence of the phenotype of the ABO blood group system:
– O — 17.6% less than healthy donors (p<0.001),
– A — 14.9% more than healthy donors (p<0.001).
No adverse reactions were recorded both with plasmapheresis in convalescent donors and transfusion reactions with transfusion of 94 units of anticonvid pathogen-reduced plasma.The accumulated data do not allow us to draw conclusions about the therapeutic effectiveness of anticovid plasma. Limitations of this study:
– 76% of transfusions were performed later than the 6th day from the onset of the disease,
– reporting clinical transfusionists have limited access to medical records located in the red zone.
It is necessary to continue to accumulate and study the experience of anticovid plasma collection and transfusion.
Keywords: donor, blood, donation, blood component, plasma, anticovid, apheresis, COVID-19.
References
1. Kuznetsov SI, Kudinova EV, Zhiburt EB. Blood collection during the period of COVID-19 infection. Healthcare Manager. 2020; 5: 41-44. (In Russ).
2. Kuznetsov SI, Averyanov EG, Shestakov EA, Zhiburt EB. Digital monitoring of the attitude to blood donation during the COVID-19 pandemic. Healthcare Manager. 2020; 6: 50-55. (In Russ).
3. Al-Riyami AZ, Schäfer R, van der Berg K, et al. Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities // Vox Sang. 2020. doi:10.1111/vox.12973.
4. Zhiburt EB, Reizman PV, Golosova SA. Apheresis — technology for the donor and recipient. Transfusiology. 2004; 5(1): 73-83. (In Russ).
5. Zhiburt EB, Chemodanov IG, Averyanov EG, et al. Complications of blood donations and its components. Transfusiology. 2019; 20(4): 275-291. (In Russ).
6. Zhiburt EB, Gubanova MN, Kodenev AT, et al. Virus-inactivated plasma for transfusion. Why a good product is slowly being introduced. Bulletin of Roszdravnadzor. 2009; 4: 14-17. (In Russ).
7. Zhiburt EB, Protopopova EB, Chemodanov IG, et al. Definitions of transfusion reactions. Transfusiology. 2019; 20(1): 65-70. (In Russ).
8. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). 7th version of 06.03.2020. (In Russ).
9. Sultanbaev US, Strelnikova EV, Ayupova RF, et al. Improvement of immunohematological studies at the Republican blood transfusion station. Transfusiology. 2015; 16(3): 25-35 (In Russ).
10. Göker H, Aladağ Karakulak E, Demiroğlu H, et al. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turk J Med Sci. 2020; 10: 3906/sag-2005-395. doi:10.3906/sag-2005-395.
11. Zhao J, Yang Y, Huang H, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. MedRxiv 2020. [Epub ahead of print]. doi: 10.1101/2020.03.11.20031096.
12. Ng D, Goldgof G, Shy B, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. 2020. doi: 10.1101/2020.05.19.201074821.
13. Shevchenko YuL, Karpov OE, Zhiburt EB. Blood transfusion: history and modernity (on the 100th anniversary of blood transfusion in Russia). Bulletin of Pirogov National Medical & Surgical Center. 2019; 14(4): 4-11. (In Russ).
